Primary Hypercholesterolaemia
Adjunct to diet when response to diet, exercise and weight reduction is inadequate.
Rosuvastatin
ROSULITOR is a rosuvastatin film-coated tablet indicated as an adjunct to diet and other non-pharmacological measures for the management of dyslipidaemia, according to the approved product information.
Rosuvastatin is indicated in adults, adolescents and children 6 years and older for lipid disorders, and in adults at high cardiovascular risk as an adjunct to correction of other risk factors.
Adjunct to diet when response to diet, exercise and weight reduction is inadequate.
For type IIb mixed dyslipidaemia as an adjunct to lifestyle measures.
As an adjunct to diet and other lipid-lowering treatments when appropriate.
For prevention of major cardiovascular events in patients at high risk for a first event.
Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase. Its primary site of action is the liver, the target organ for cholesterol lowering.
How Rosulitor works
RosulitorRosuvastatin HMG-CoA Reductase Inhibition Increased Hepatic LDL Receptors Reduced LDL-C and VLDL ParticlesRosuvastatin reduces LDL-C, total cholesterol and triglycerides, and increases HDL-C.
A therapeutic effect is obtained within 1 week; the maximum response is usually achieved by 4 weeks.
Myalgia, myopathy and, rarely, rhabdomyolysis have been reported. Patients should promptly report unexplained muscle pain, weakness or cramps.
Do not use in active liver disease, severe renal impairment, myopathy, pregnancy or lactation, or with ciclosporin. Refer to approved prescribing information for full warnings and interactions.
ROSULITOR is a rosuvastatin film-coated tablet indicated as an adjunct to diet and other non-pharmacological measures for the management of dyslipidaemia, according to the approved product information.
Rosuvastatin is indicated in adults, adolescents and children 6 years and older for lipid disorders, and in adults at high cardiovascular risk as an adjunct to correction of other risk factors. Indications include primary hypercholesterolaemia, mixed dyslipidaemia, familial hypercholesterolaemia and cardiovascular risk reduction.
Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase. Its primary site of action is the liver, the target organ for cholesterol lowering.
Administer orally once daily, at any time of day, with or without food. Treatment should begin with a cholesterol-lowering diet that continues during therapy. Dose selection and adjustment should be individualised according to the treatment goal, response and patient risk factors.
Rosuvastatin reduces LDL-C, total cholesterol and triglycerides, and increases HDL-C.
A therapeutic effect is obtained within 1 week; the maximum response is usually achieved by 4 weeks.
Myalgia, myopathy and, rarely, rhabdomyolysis have been reported. Patients should promptly report unexplained muscle pain, weakness or cramps. Do not use in active liver disease, severe renal impairment, myopathy, pregnancy or lactation, or with ciclosporin. Refer to approved prescribing information for full warnings and interactions.
Rosulitor is available as Rosuvastatin 20 mg reddish-brown film-coated tablets, in boxes of 30 or 100 tablets, following the United States Pharmacopeia standard.
Each film-coated tablet contains rosuvastatin calcium USP equivalent to rosuvastatin 20 mg. The finished-product specification references USP 47 for identity, dissolution and assay testing.